ATE499933T1 - Verwendung von betain zur behandlung von claudicatio intermittens - Google Patents

Verwendung von betain zur behandlung von claudicatio intermittens

Info

Publication number
ATE499933T1
ATE499933T1 AT04737684T AT04737684T ATE499933T1 AT E499933 T1 ATE499933 T1 AT E499933T1 AT 04737684 T AT04737684 T AT 04737684T AT 04737684 T AT04737684 T AT 04737684T AT E499933 T1 ATE499933 T1 AT E499933T1
Authority
AT
Austria
Prior art keywords
treating
describes
claudicatio
intermittens
betain
Prior art date
Application number
AT04737684T
Other languages
English (en)
Inventor
Jallal Messadek
Original Assignee
Jallal Messadek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jallal Messadek filed Critical Jallal Messadek
Application granted granted Critical
Publication of ATE499933T1 publication Critical patent/ATE499933T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)
AT04737684T 2003-07-15 2004-07-08 Verwendung von betain zur behandlung von claudicatio intermittens ATE499933T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE2003/0408A BE1015608A6 (fr) 2003-07-15 2003-07-15 Traitement des arterites.
PCT/BE2004/000101 WO2005004854A2 (fr) 2003-07-15 2004-07-08 Utilisation de la betaine pour le traitement des arterites

Publications (1)

Publication Number Publication Date
ATE499933T1 true ATE499933T1 (de) 2011-03-15

Family

ID=33569382

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04737684T ATE499933T1 (de) 2003-07-15 2004-07-08 Verwendung von betain zur behandlung von claudicatio intermittens

Country Status (11)

Country Link
US (2) US8343947B2 (de)
EP (1) EP1656131B1 (de)
AT (1) ATE499933T1 (de)
BE (1) BE1015608A6 (de)
CA (1) CA2569537A1 (de)
DE (1) DE602004031631D1 (de)
DK (1) DK1656131T3 (de)
ES (1) ES2361915T3 (de)
PL (1) PL1656131T3 (de)
PT (1) PT1656131E (de)
WO (1) WO2005004854A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1013958A6 (fr) * 2001-02-05 2003-01-14 Messadek Jallal Antagonistes glycoproteiques.
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
EA017982B1 (ru) 2005-02-24 2013-04-30 ДИФФЬЮЖН ФАРМАСЬЮТИКАЛЗ ЭлЭлСи Фармацевтическая композиция на основе транскаротиноидов и способы лечения опухоли
BRPI0610249A2 (pt) 2005-04-27 2010-06-08 Jallal Messadek associação ou combinação farmacêutica, composição farmacêutica, processo de co-cristalização e o uso de insulina ou análogo de insulina
AU2008319225B2 (en) * 2007-10-31 2016-09-29 Diffusion Pharmaceuticals Llc A new class of therapeutics that enhance small molecule diffusion
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
US10130689B2 (en) 2009-06-22 2018-11-20 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
EP2575487B1 (de) 2010-06-02 2017-10-18 Diffusion Pharmaceuticals Llc Orale formulierungen aus bipolaren transkarotinoiden
RU2523412C1 (ru) * 2013-02-25 2014-07-20 Общество с ограниченной ответственностью "МЕЖДУНАРОДНЫЙ ЦЕНТР КЛИНИЧЕСКОЙ ЛИМФОЛОГИИ" Способ лечения больных облитерирующими заболеваниям и артерий нижних конечностей
EP3432929A4 (de) 2016-03-24 2019-11-27 Diffusion Pharmaceuticals LLC Verwendung von bipolaren transkarotinoiden mit chemotherapie und strahlentherapie zur behandlung von krebs

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE644568C (de) * 1934-04-19 1937-05-07 Bristol Aeroplane Co Ltd Kopierfraesmaschine
FR2590M (fr) 1963-03-12 1964-06-15 Albert Beaufour Nouvelles associations antinévralgiques a tolérance améliorée.
US3577534A (en) * 1968-06-20 1971-05-04 Canada Packers Ltd Stable orally active heparinoid complexes
FR2119889A1 (en) * 1970-12-31 1972-08-11 Vegetti Tiberio Deoxyribonucleic acid compsns - for treating degenerating mesenchyma,parenchyma or arteriosclerosis
GB1509979A (en) * 1975-11-28 1978-05-10 Fisons Ltd Pharmaceutical compositions containing aspirin or indomethacin
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
FR2403799A2 (fr) 1977-09-27 1979-04-20 Union Pharma Scient Appl Solution d'acide acetylsalicylique extemporanee injectable
US4605548A (en) * 1983-05-31 1986-08-12 Nitto Electric Industrial Co., Ltd. Drug administration material
GB8325627D0 (en) * 1983-09-24 1983-10-26 Scras Therapeutic compositions
DK162986A (da) * 1985-04-12 1986-10-13 Forest Laboratories Terapeutisk middel i enhedsdosisform
AU607172B2 (en) * 1986-12-22 1991-02-28 Cygnus, Inc. Diffusion matrix for transdermal drug administration
HU210122B (en) 1988-03-23 1995-02-28 Biorex Kutato Fejlesztoe Kft Process for production of composition against thromboembolytic conditions of circulating system and heart
US4902718A (en) * 1988-04-08 1990-02-20 Bayless Robert K Calcium homeostasis compositions and methods for controlling calcium metabolism
EP0347864A3 (de) 1988-06-24 1992-04-01 Andries Johannes Cornelus Strydom Antiatherosklerose-Mittel
IT1226386B (it) 1988-07-08 1991-01-15 Chiesi Farma Spa Procedimento di preparazione di morniflumato e analoghi.
US4968719A (en) * 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5405614A (en) * 1992-04-08 1995-04-11 International Medical Associates, Inc. Electronic transdermal drug delivery system
US5342621A (en) * 1992-09-15 1994-08-30 Advanced Cardiovascular Systems, Inc. Antithrombogenic surface
US5876780A (en) * 1993-04-29 1999-03-02 Cultor, Ltd. Compositions for treating coccidiosis
US5716941A (en) * 1993-07-07 1998-02-10 Biogenesys Use of methyl donor compounds to treat neurological dysfunction associated with immune defects
US5814599A (en) * 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
AU1265295A (en) * 1993-12-10 1995-06-27 Sami A. Hashim Reducing likelihood of vascular disorders in susceptible patients
US6355166B1 (en) * 1994-08-25 2002-03-12 The University Of Iowa Research Foundation Magnetically enhanced composite materials and methods for making and using the same
US6056958A (en) * 1994-12-09 2000-05-02 Dupont Pharmaceuticals Method of treatment of arterial and venous thromboembolic disorders
US5961999A (en) * 1995-06-08 1999-10-05 Wella Aktiengesellschaft Method of skin care using a skin care preparation containing a betaine ester and an α-hydroxy acid
JP3119430B2 (ja) 1995-07-25 2000-12-18 大鵬薬品工業株式会社 水酸基ラジカル消去剤
US6162926A (en) * 1995-07-31 2000-12-19 Sphere Biosystems, Inc. Multi-substituted fullerenes and methods for their preparation and characterization
LV11727B (en) 1995-08-21 1997-08-20 Kalvins Ivars Pharmaceutical composition
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
AU2260397A (en) * 1996-01-31 1997-08-22 Trustees Of The University Of Pennsylvania, The Remote control drug delivery device
US5688499A (en) * 1996-03-13 1997-11-18 Queen's University At Kingston Antagonism of endothelin actions
SE9601396D0 (sv) 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 2
US5880098A (en) * 1996-04-12 1999-03-09 Pharmacia & Upjohn Aktiebolag Therapeutic treatment
SE9601395D0 (sv) 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 1
IL119029A0 (en) * 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US6008221A (en) * 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6258859B1 (en) 1997-06-10 2001-07-10 Rhodia, Inc. Viscoelastic surfactant fluids and related methods of use
JP2002506024A (ja) 1998-03-13 2002-02-26 メルク エンド カムパニー インコーポレーテッド 急性冠動脈虚血症候群および関連状態に対する併用療法および組成物
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
IL139008A0 (en) * 1998-04-14 2001-11-25 Gen Hospital Corp Methods for treating neuropsychiatric disorders
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
BR9914815A (pt) * 1998-10-30 2001-07-03 Merck Patent Gmbh Composições para tratamento e prevenção de doenças cardiovasculares
JP2000143486A (ja) 1998-11-12 2000-05-23 Lion Corp 皮膚外用剤
BE1012495A3 (fr) 1999-03-02 2000-11-07 Messadek Jallal La glycine-betaine pour son usage antithrombotique.
US7608640B2 (en) * 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
BE1013958A6 (fr) * 2001-02-05 2003-01-14 Messadek Jallal Antagonistes glycoproteiques.
BE1012546A6 (fr) 1999-03-10 2000-12-05 Messadek Jallal La betaine et ses derives pour leur usage antithrombotique.
DE19910682B4 (de) 1999-03-10 2004-09-02 Dierkes, Jutta, Dr. Verwendung eines Kombinationspräparates zur Therapie einer Fibrat-induzierten Hyperhomocysteinämie
BE1012712A6 (fr) 1999-06-10 2001-02-06 Messadek Jallal Peptides antithrombotiques.
DE10004651A1 (de) 2000-02-03 2001-08-16 Jutta Dierkes Kombination von blutdrucksenkenden Wirkstoffen mit Wirkstoffen, die den Homocysteinspiegel zu senken vermögen
CA2407027C (en) * 2000-04-20 2011-02-15 Rtp Pharma Inc. Improved water-insoluble drug particle process
JP2004501190A (ja) 2000-06-23 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
FR2811227A1 (fr) * 2000-07-07 2002-01-11 Philippe Maincent Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
DE10038539A1 (de) 2000-08-03 2002-02-21 Bosch Gmbh Robert Verfahren und Vorrichtung zur energiesparenden Dichtheitsprüfung einer Brennstofftankanlage insbesondere eines Kraftfahrzeuges
WO2002042272A2 (en) * 2000-11-20 2002-05-30 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
AU2002221934A1 (en) 2000-12-16 2002-06-24 Aventis Pharma Deutschland Gmbh Health promoting compositions
FI114538B (fi) * 2001-01-12 2004-11-15 Finnfeeds Finland Ltd Glysiinibetaiinin käyttö verenpainetta alentavan tuotteen valmistukseen
EP1408949B1 (de) * 2001-02-05 2007-12-19 Jallal Messadek Antihaemorrhagische, betain-enthaltende zusammenseuzungen
EP1363604A2 (de) 2001-02-14 2003-11-26 Glaxo Wellcome S.A. Pharmazeutische formulierung
US20040072750A1 (en) * 2001-05-03 2004-04-15 David Phillips Compounds and methods for the modulation of CD154
US6531171B2 (en) * 2001-07-03 2003-03-11 Nutricia Usa, Inc. Food products containing betaine
WO2003020260A1 (en) * 2001-08-31 2003-03-13 Metaproteomics, Llc Arginine compositions for coordinate modification of multiple cardiovascular risk factors
US20030170223A1 (en) * 2002-02-01 2003-09-11 Board Of Trustees Of Michigan State University Pulmonary vasodilator surfactant compositions and method of use
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
US20060160896A1 (en) * 2002-02-04 2006-07-20 Jallal Messadek Therapeutic treatment
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
EP2402753A1 (de) * 2002-03-11 2012-01-04 Momenta Pharmaceuticals, Inc. Analyse von sulfatierten Polysacchariden
TW200307551A (en) 2002-04-16 2003-12-16 Tanabe Seiyaku Co Phenol compound, process for preparing the same and synthetic intermediate thereof
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040067986A1 (en) * 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
DE60238283D1 (de) * 2002-11-25 2010-12-23 Jallal Messadek Betain und Salicylsäure Zusammensetzungen
ES2278314T3 (es) 2003-04-17 2007-08-01 Jallal Messadek Formulaciones orales para la liberacion controlada de la betaina.
DE10319376B4 (de) 2003-04-30 2007-01-04 Uponor Innovation Ab Pressbacke für ein Presswerkzeug zum Verpressen von Fittingen, Presswerkzeug und Werkzeug zum axialen Aufschieben einer Hülse
US7097968B2 (en) * 2003-07-10 2006-08-29 General Atomics Methods and compositions for assaying homocysteine
WO2005011645A2 (en) 2003-08-04 2005-02-10 Jallal Messadek Selected betaines and their uses
US20060128657A1 (en) 2003-08-04 2006-06-15 Jallal Messadek Selected betaines and their uses
CA2534660A1 (en) 2003-08-05 2005-02-10 Galephar M/F Single unit pharmaceutical composition comprising a mixture of a fibrate and an homocysteine reducing agent
WO2005065675A1 (en) 2004-01-07 2005-07-21 Premacs International Pty. Ltd. Method of treatment
AU2005234782A1 (en) * 2004-04-23 2005-11-03 Celgene Corporation Methods of using and compositions comprising thalidomide for the treatment and management of pulmonary hypertension
BE1016128A6 (fr) * 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006086856A1 (en) * 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
BRPI0610249A2 (pt) * 2005-04-27 2010-06-08 Jallal Messadek associação ou combinação farmacêutica, composição farmacêutica, processo de co-cristalização e o uso de insulina ou análogo de insulina

Also Published As

Publication number Publication date
EP1656131B1 (de) 2011-03-02
US8343947B2 (en) 2013-01-01
US20100210608A1 (en) 2010-08-19
ES2361915T3 (es) 2011-06-24
DK1656131T3 (da) 2011-06-14
WO2005004854A2 (fr) 2005-01-20
PT1656131E (pt) 2011-06-07
BE1015608A6 (fr) 2005-06-07
EP1656131A2 (de) 2006-05-17
US20130096195A1 (en) 2013-04-18
WO2005004854A3 (fr) 2005-06-16
CA2569537A1 (fr) 2005-01-20
PL1656131T3 (pl) 2011-07-29
DE602004031631D1 (de) 2011-04-14

Similar Documents

Publication Publication Date Title
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE457166T1 (de) Orale zusammensetzungen zur behandlung von diabetes
EA200601846A1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
EA200701296A1 (ru) 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства
DE60322436D1 (de) Verabreichung von capsaicinoiden
MXPA05008649A (es) Terapia de combinacion para el tratamiento de desordenes inmunoinflamatorios.
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
ATE499933T1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
TW200616644A (en) Medicine for prevention or treatment of diabetes
ATE439833T1 (de) Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
DE60214527D1 (de) Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
DE602006020838D1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
DE60108130D1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DE602004029993D1 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
ATE341323T1 (de) Verwendung von darifenacin zur behandlung des harndrangs
ATE407925T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
SE0100873D0 (sv) Method of treatment
TW200610524A (en) Medicine for prevention or treatment of diabetes
ATE337790T1 (de) Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen
TW200608965A (en) Medicine for prevention or treatment of diabetes
ATE464051T1 (de) Kombination aus levosimendan und einer kalziumquelle zur behandlung von herzinsuffizienz
DE60108775T8 (de) Methode zur behandlung von schlaganfall

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1656131

Country of ref document: EP